伊克萨佐米布,达拉图穆马布和低剂量德克萨美沙在中等适应新诊断多发性骨髓瘤的患者:一个开放的标签2期试验
Kaz Groen1,2, Claudia A M Stege1,2, Kazem Nasserinejad3,4
1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands.
伊克萨佐米布-达拉图穆马布-低剂量德克萨米在新诊断的多发性骨髓瘤 (NDMM) 患者中显示出安全性和改善生活质量. 然而,由于ixazomib毒性的有限疗效,需要为中等适应症患者提供更好的治疗选择.
科学领域:
- 血液学 血液学 血液学
- 临床瘤学临床瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤的结果各不相同,受患者脆弱性的影响.
- 非移植合格的新诊断多发性骨髓瘤 (NDMM) 患者需要量身定制的治疗策略.
研究的目的:
- 评估Ixazomib-Daratumumab-低剂量德克萨米他 (Ixa-Dara-dex) 在中等适应性NDMM患者的疗效和安全性.
- 评估这种疗法对生活质量和治疗耐受性的影响.
主要方法:
- 第二阶段多中心HOVON-143研究,涉及中等适应性NDMM患者.
- 治疗Ixa-Dara-dex的9个诱导周期,然后进行维持治疗.
- 评估整体应答率,无进展生存率,整体生存率和生活质量.
主要成果:
- 诱导疗法总体响应率为71%的诱导疗法.
- 平均无进展生存时间为18.2个月;3年总生存率为83%.
- 整体生活质量的显著改善,但由于多神经病变,常常会改变ixazomib的剂量.
结论:
- 伊克萨-达拉-德克斯是安全的,并改善了中等适应性NDMM患者的生活质量.
- 艾克萨佐米布的有限疗效和毒性阻碍了长期耐受性.
- 需要为脆弱的NDMM人群提供更有效和更耐受的治疗方案.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
相关概念视频
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Targeted Cancer Therapies
There are several types of targeted therapies against...
